Anixa Biosciences, Inc. · NASDAQ:ANIX
Anixa Biosciences — Shareholder Meeting (March 2024)
34 slides from Anixa Biosciences's shareholder meeting presentation, Mar 22, 2024
Slide 1: Presentation at Annual Shareholder Meeting
Aanixa BOS cE Nice Dr. Amit Kumar Chairman and CEO NASDAQ:ANIX March 21, 2024 Presentation at Annual Shareholder Meeting
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences’ current
Slide 3: Anixa Snapshot
— Anixa Snapshot Clinical-stage company developing first-in-class products to treat & prevent cancer Robust Strong Clinical Strong Financial Pipeline Data Profile Ss) © Key Significant TAM Partnerships Opportunity 0 3 < 6 s
Slide 4: Clinical Programs & Development Partnerships
— Clinical Programs & Development Partnerships THERAPEUTIC. AREA Oncology Oncology Oncology MECHANISM OF ACTION Vaccine Vaccine CART Therapeutic INDICATION Breast Cancer Ovarian Cancer Ovarian Cancer / Other Solid Tumors GEOGRAPHIC. RIGHTS Global Global Global UPCOMING MILESTONES Additional Phase Ph
Slide 5: Vaccine Program
VACCINE PROGRAM Background
Slide 6: Preventative Cancer Vaccines Have Failed
Aanixa Preventative Cancer Vaccines Have Failed ...except for cancers driven by infectious agents. B Virus (HBV) Human Papillomavirus (HPV) Human papillomavirus (HPV) is a common sexually Hepatitis Bis caused by the hepatitis B virus (HBV). Hepatitis transmitted virus that can cause genital warts an
Slide 7: Why Have Preventative Cancer Vaccines Failed?
Aanixa — Why Have Preventative Cancer Vaccines Failed? Cancer vaccines typically target proteins overexpressed on tumors. Normal Cell HER2+ cell vez tna ence 4g a ot Vy, Ze, a. fe = y eS WS oa a CPI BS ann Mechanisms exist to limit immune response Autoimmune disorders are created by against self-pro
Slide 8: Retired Tissue-Specific Proteins Hypothesis
Aanixa RETIRED TissuE-SPECIFIC PROTEINS HYPOTHESIS A New Paradigm for Prophylactic Cancer Vaccines Proposed by the late Dr. Vincent Tuohy, Cleveland Clinic
Slide 9: Retired Tissue-Specific Proteins for Prophylactic Cancer Vaccines
Retired Tissue-Specific Proteins for Prophylactic Cancer Vaccines Retired tissue-specific protein definition: © Protein that is expressed, in a particular tissue, at certain times in life for a particular function © After function is no longer necessary, that protein is no longer expressed The prote
Slide 10: Breast Cancer Vaccine
Breast Cancer Vaccine
Slide 11: Breast Cancer Vaccine: Retired Tissue Specific Protein
Protein Retired Tissue Specific Pro’ in Expressed at periods of life, but no longer expressed as we . age g-Lactalbumin —>" ous ne. 7A 7 A Mi ( RA Ae, 4 on ‘ ii ! Galactose Glucose Breast Cancer Vaccine: Retired Tissue Specific a-LACTALBUMIN Expressed only in the breast and only during lactation + E
Slide 12: Proof of Concept - Published in 2012
Proof of Concept* -Published in 2012 LITTER Vaccinated mouse © After vaccination mice were mated and allowed to have alitter. © The pups were perfectly normal at birth. © Mothers were unable to produce milk. This proves that vaccination targeting a-lactalbumin enables the immune system to destroy al
Slide 13: Pre-Clinical Studies: Vaccination Prevents Breast Cancer
Aanixa — Pre-Clinical Studies: Vaccination Prevents Breast Cancer Well-Tolerated Robust Pre-Clinical Response MMTV-neu Mice 3 8 Tumor Size (mm?) NN \ f Vaccinated Controls 100% of a-LACTALBUMIN vaccinated mice did not piel ic cater develop breast cancer Ps Vaccinated mice did not exhibit autoimmune
Slide 14: Phase 1 Trial
— Phase 1 Trial Conducted by Cleveland Clinic, funded by U.S. Department of Defense (DOD) An open-tabel Phase 1 dose-escalation trial Participants will receive three vaccinations, each two weeks apart, and will be closely monitored for side effects and immune response 18-24 Patients who have been tr
Slide 15: Positive Clinical Results
Positive Clinical Results * Enrollment of women who have had TNBC and have undergone standard of care, but are at risk of recurrence = 42% of TNBC survivors will relapse within 5 years = MTD reached * Data from all vaccinated women tested to date presented at San Antonio Breast Cancer Symposium in D
Slide 16: Opportunity
Opportunity = Successive to appropriate clinical trials, a prophylactic (preventative) vaccines may be eventually administered to the total eligible population = Multi-billion Dollar Market opportunity U.S. (Total Eligible Population) = Over 3.8 MM breast cancer survivors in the US! * Millions more
Slide 17: Thoughts About Adaptive Phase 2/3 Trial
— Thoughts About Adaptive Phase 2/3 Trial © Multiple Sites (10-20)- Academic as well as community (including sites that may enable diverse group of participants) © Roughly 600 TNBC Survivors (final numbers to be determined) —Standard of Care (SOC) + Vaccine —SOC only Randomized but not blinded Effic
Slide 18: Ovarian Cancer Vaccine
ic i < SS ¢ Ovarian Cancer Vaccine
Slide 19: Novel Target: ED-AMHR2
Novel Target: ED-AMHR2 Also a retired tissue-specific self-protein Cleveland Clinic Collaboration | Funding & NATIONAL Collaboration | iNsrrure Extracellular domain of the anti-mullerian hormone receptor 2 (ED-AMHR2) is primarily expressed in the ovaries, but disappears as a woman reaches and advanc
Slide 20: Additional Thoughts on Vaccines
— Additional Thoughts on Vaccines © We may be able to use the Breast Cancer Vaccine in the neo-adjuvant setting —Animal data shows that the the vaccine will inhibit growth in 471 Tumors —Could we use biopsy and IHC to verify alpha- lactalbumin expression before utilization? © Ovarian Cancer Vaccine
Slide 21: Therapeutic CAR-T Program: Ovarian Cancer
ic = 5 s THERAPEUTIC CAR-T PROGRAM A, Ovarian Cancer
Slide 22: CAR-T Technology
—— CAR-T Technology Background & opportunity Chimeric Antigen Receptor T cell CAR- T has made great inroad: Cell cancers Our Opportuni = Durable responses (50-80% of patients) = Multibillion dollar valuations and big pharma deals o Novaniis - First approved product by FDA * Kymriah for Acute Lymphob
Slide 23: CAR-T Procedure: Chimeric Antigen Receptor-T cell
Aanixa — CAR-T Procedure: Chimeric Antigen Receptor-T cell @ Collect patience’s @©CAR-T/TCR-T cell — ira ~ cM @ Isolation of and quality contro! T lymphocytes @ Activation and @ Genetic CAR/TCR amplification engineering
Slide 24: Anixa's Unique & Targeted CAR-T Approach for Solid Tumors
Aanixa Anixa’s Unique & Targeted CER-T Approach for Solid Tumors Anixa’s CAR-T Program for Ovarian Cancer Other CAR-T Programs Follicle Stimulating Hormone Receptor (“FSHR")- Novartis, JUNO, KITE and others working on B-Cell mediated CAR-T Technology cancers Chimeric Endocrine Receptor-T cell T cell
Slide 25: exiuey
exiuey (toned by BSE ‘oWsd HE sis, i £1210 ysealg ypewors ‘aunseqUy jews snuein eoyoesL PUe!g PIOJAYL smuukuy eels 198NW 1B11¥S puelg fuentes 121801 evaded Bun Jonny Aeupry, eel ojo ueig e104 joy weg winjaqaieg werg puelo jeveipy Only in Fetal Thymus = FSHR ONLY Expressed in Ovaries and Testes and T
Slide 26: Our FSHR-Mediated CAR-T Technology
Our FSHR-Mediated CAR-T Technology Dual mechanism of action = Many tumors have blood vessels where FSHR is expressed even though healthy tissue does not show such expression o Physiologically, FSHR may be helpful in enabling tumors to create vasculature o Elegant target: outside of the tumor margin,
Slide 27: Intraperitoneal Delivery (IP) Is Another Key Advantage
Intraperitoneal Delivery (IP) Is Another Key Advantage * Most, if not all, ovarian cancer lesions remain within the peritoneal cavity and ascites = By delivering through an IP catheter, the engineered T cells will largely remain in the peritoneal cavity = Very few, if any, engineered T cells escape
Slide 28: The First Potential Anti-Angiogenic CAR-T Therapy
Aanixa — The First Potential Anti- Angiogenic CAR-T Therapy Exclusive worldwide license from The Wistar Institute We believe our CER-T approach will work in solid tumors, especially ovarian cancer, where others Current Phase 1 Trial at Moffitt Cancer Center have failed Treated Three Patients at Subt
Slide 29: Slide 29
Slide 30: Capital Efficient
Capital Efficient Low-cost business model = Develop programs with partners v Leverage existing infrastructure of partner v Maintain low overhead and cash burn v Allows for multiple orthogonal projects = Potentially out-license programs to pharma for late-stage clinical development and commercializat
Slide 31: Financial Summary
Aanixa Financial Summary NASDAQ:ANIX S24M cash, cash equivalents and short-term investments as of January 31, 2024 ~$5 - 6M annual cash burn since 2017 32M shares outstanding as of January 31, 2024 OS No debt
Slide 32: Value-Creating Near-Term Clinical Catalysts
Aanixa Value-Creating Near-Term Clinical Catalysts Multiple catalysts over the next 12 months across our clinical pipeline ole | eam | Oncology Breast Cancer Vaccine Phase la Additional Phase Ta data ing! phase 1a data release release Preliminary Phase Ib data Additional Phase 1b data Breast Cancer
Slide 33: Investment Highlights
Aanixa Investment Highlights (ist) all Strong Clinical Data Strong Financial Profile 2 clinical trials in progress, ~$24M of cash, no debt, showing positive results and capital efficient a fix y business model “Sy © Robust Pipeline focused on prevention or treatment of cancer Key Partnerships The Cl
Slide 34: Thank you
Aanixa BIOSCIENCES Thank you CONTACT INFORMATION: Amit Kumar, Ph.D. Chairman & CEO ak@anixa.com Mike Catelani President, COO & CFO. mceatelani@anixa.com NASDAQ: ANIX